Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 101–200 of 1,004
Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine
Sureshchandra, S., Lewis, S. A., Doratt, B. M., Jankeel, A., Coimbra Ibraim, I., & Messaoudi, I. (2021) · JCI Insight · doi:10.1172/jci.insight.153201 · Cited by 91
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19
Hardt, K., Vandebosch, A., SADOFF, J. C., Gars, M. L., Truyers, C., Lowson, D., Dromme, I. V., Vingerhoets, J., Kamphuis, T., Scheper, G. C., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00506-0 · Cited by 96
Vaccine development: Current trends and technologies
Poria, R., Kala, D., Nagraik, R., Walia, Y., Dhir, S., Singh, B., Kaushik, N. K., Noorani, M. S., Kaushal, A., & Gupta, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122331 · Cited by 99
Oral antiviral treatments for COVID-19: opportunities and challenges
Rahmah, L., Abarikwu, S. O., Arero, A. G., Essouma, M., Jibril, A. T., Fal, A., Flisiak, R., Makuku, R., Marquez, L. P., Mohamed, K., et al. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00388-7 · Cited by 91
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C., Gervais, A., Voyer, T. L., Bizien, L., Zamecnik, C. R., Philippot, Q., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8966 · Cited by 90
“RNA vaccines are highly effective at protecting against severe COVID-19 pneumonia ( 24 , 25 ).”
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 89
Xu, K., Wang, Z., Qin, M., Gao, Y., Luo, N., Xie, W., Zou, Y., Wang, J., & Ma, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113156 · Cited by 100
“Clinical trials have shown COVID-19 vaccines to be immunogenic against SARS-CoV-2 infection and safe, with their efficacy ranging from 86% and 95% for the messenger RNA (mRNA) vaccines BNT162b2 (19) and mRNA-1273 (20), respectively, to 74% for the AZD1222 (ChAdOx1 nCoV-19) vaccine (21) in those aged 18 years and older.”
BackgroundBritton, A., Fleming-Dutra, K. E., Shang, N., Smith, Z., Dorji, T., Derado, G., Accorsi, E. K., Ajani, U. A., Miller, J., Schrag, S. J., et al. (2022) · JAMA · doi:10.1001/jama.2022.2068 · Cited by 84
Curti, F., Fortunati, S., Knoll, W., Giannetto, M., Corradini, R., Bertucci, A., & Careri, M. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02405 · Cited by 84
Wang, C. Y., Hwang, K.-P., Kuo, H.-K., Peng, W.-J., Shen, Y.-H., Kuo, B.-S., Huang, J.-H., Liu, H., Ho, Y.-H., Lin, F., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157707 · Cited by 87
“The long-lasting nature of humoral B and T cell immune responses of UB-612 (100 μ g dose group) could be an advantage when short durability of a vaccine becomes a growing concern (12, 40, 41).”
Richard, S. A., Pollett, S. D., Fries, A. C., Berjohn, C. M., Maves, R. C., Lalani, T., Smith, A. G., Mody, R. M., Ganesan, A., Colombo, R. E., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.51360 · Cited by 90
Tracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 97
Linking vaccine adjuvant mechanisms of action to function
Ben‐Akiva, E., Chapman, A. P., Mao, T., & Irvine, D. J. (2025) · Science Immunology · doi:10.1126/sciimmunol.ado5937 · Cited by 84
Khan, N. A., Al-Thani, H. A. S., & El-Menyar, A. A. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102246 · Cited by 87
“A recent Pfizer research [16], which included data from over 44 000 people, indicated that after 6 months, vaccination protection dropped from 96.”
Monge, S., Rojas-Benedicto, A., Olmedo, C., Mazagatos, C., José Sierra, M., Limia, A., Martín-Merino, E., Larrauri, A., Hernán, M. A., Moreno, D., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00292-4 · Cited by 81
Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
Gartlan, C., Tipton, T., Salguero, F. J., Sattentau, Q. J., GORRINGE, A. R., & Carroll, M. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.882972 · Cited by 87
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Tang, P., Coyle, P., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Al-Kanaani, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 83
Barin, B., Kasap, U., Selçuk, F., Volkan, E., & Uluçkan, Ö. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00305-0 · Cited by 90
Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination
Klompas, M. (2021) · JAMA · doi:10.1001/jama.2021.19063 · Cited by 85
O’Brien, M. N., Costa, A. P., Cebrero, Y. M., Joseph, J., Sarode, A., Zang, N., Kim, L. J., Hofmann, K., Wang, S., Goyon, A., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00390 · Cited by 83
Recent Advances and Prospects in RNA Drug Development
Tani, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212284 · Cited by 81
Collier, A.-R. Y., Brown, C., McMahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D. B., Ansel, J. L., Rowe, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn6150 · Cited by 91
COVID-19 vaccine and booster hesitation around the world: A literature review
Shah, A., & Coiado, O. C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1054557 · Cited by 82
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Rzymski, P., Camargo, C. A., Fal, A., Flisiak, R., Gwenzi, W., Kelishadi, R., Leemans, A., Nieto, J. J., Ozen, A., Perc, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111299 · Cited by 86
mRNA vaccines: The future of prevention of viral infections?
Rzymski, P., Szuster‐Ciesielska, A., Dzieciątkowski, T., Gwenzi, W., & Fal, A. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28572 · Cited by 79
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Suah, J. L., Husin, M., Tok, P. S. K., Tng, B. H., Thevananthan, T., Low, E. V., Appannan, M. R., Muhamad Zin, F., Mohd Zin, S., Yahaya, H., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.028 · Cited by 76
“…) I T s e e ( a H 4 ( v a ( H u u f f h 1 l NTRODUCTION Since early 2021, clinical trials ( Falsey et al., 2021 ; anriover et al., 2021 ; Thomas et al., 2021 ) and real-world tudies on vaccine effectiveness ( Jara et al., 2021 ; Lopez Bernal t al., 2021 ; Suah et al., 2021 ) have…”
Kahn, R., Schrag, S. J., Verani, J. R., & Lipsitch, M. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac015 · Cited by 76
Vaccine Effectiveness Against Long COVID in Children
Razzaghi, H., Forrest, C. B., Hirabayashi, K., Wu, Q., Allen, A. J., Rao, S., Chen, Y., Bunnell, H. T., Chrischilles, E. A., Cowell, L. G., et al. (2024) · PEDIATRICS · doi:10.1542/peds.2023-064446 · Cited by 80
Cancer vaccines: Target antigens, vaccine platforms and preclinical models
Ruzzi, F., Riccardo, F., Conti, L., Tarone, L., Semprini, M. S., Bolli, E., Barutello, G., Quaglino, E., Lollini, P., & Cavallo, F. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101324 · Cited by 81
“The rapid development and global deployment of COVID-19 RNA vaccines further demonstrated the scalability and adaptability of this technology (Thomas et al., 2021; Zhang et al., 2023a).”
Toledo-Romaní, M. E., Carmenate, M. G., Valenzuela‐Silva, C., Rodríguez, W. B., Martínez-Pérez, M., Rodríguez-González, M., Paredes-Moreno, B., Mendoza-Hernández, I., González-Mugica, R., Samón-Tabío, O., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100423 · Cited by 80
mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies
Xie, Z., Lin, Y., Steichen, J. M., Ozorowski, G., Kratochvil, S., Ray, R., Torres, J. L., Liguori, A., Kalyuzhniy, O., Wang, X., et al. (2024) · Science · doi:10.1126/science.adk0582 · Cited by 75
“TheeffectivenessofthemRNA-1273andBNT162b2 SARS-CoV-2vaccineshavebroughttheprom-ise of mRNA-based vaccines to the fore( 40 , 41 ).”
BackgroundContribution of low population immunity to the severe Omicron BA.2 outbreak in Hong Kong
Chen, L.-L., Abdullah, S. M. U., Chan, W.-M., Chan, B. P.-C., Ip, J. D., Chu, A. W.-H., Lu, L., Zhang, X., Zhao, Y., Chuang, V. W.-M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31395-0 · Cited by 72
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Ponce‐de‐León, S., Torres, M., Soto-Ramírez, L. E., Calva, J. J., Santillán‐Doherty, P., Carranza-Salazar, D. E., Carreño, J. M., Carranza, C., Juárez, E., Carreto-Binaghi, L. E., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00662-6 · Cited by 75
A Comparison of Vaccine Hesitancy of COVID-19 Vaccination in China and the United States
Liu, T., He, Z., Huang, J. V., Yan, N., Chen, Q., Huang, F., Zhang, Y., Akinwunmi, O. M., Akinwunmi, B. O., Zhang, C. J. P., et al. (2021) · Vaccines · doi:10.3390/vaccines9060649 · Cited by 75
Minocha, P. K., Better, D. J., Singh, R. K., & Hoque, T. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.06.035 · Cited by 75
Arashiro, T., Arima, Y., Muraoka, H., Sato, A., Oba, K., Uehara, Y., Arioka, H., Yanai, H., Kuramochi, J., Ihara, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac635 · Cited by 70
Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 76
Ma, Y., Deng, J., Liu, Q., Du, M., Liu, M., & Liu, J. (2022) · Vaccines · doi:10.3390/vaccines10020246 · Cited by 74
Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers
Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · doi:10.1101/2021.08.26.21262468 · Cited by 69
Mörz, M. (2022) · Vaccines · doi:10.3390/vaccines10101651 · Cited by 74
Clinical validation of engineered CRISPR/Cas12a for rapid SARS-CoV-2 detection
Nguyễn, L. T., Rananaware, S. R., Pizzano, B. L. M., Stone, B. T., & Jain, P. (2022) · Communications Medicine · doi:10.1038/s43856-021-00066-4 · Cited by 68
Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?
Brüssow, H., & Zuber, S. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13997 · Cited by 72
“Against severe COVID-19 VE was still 96.7% (Thomas et al., 2021).”
BackgroundInfluentialA Perspective on Current Flavivirus Vaccine Development: A Brief Review
Dutta, S. K., & Langenburg, T. (2023) · Viruses · doi:10.3390/v15040860 · Cited by 71
“Additionally, BionTech/Pfizer developed their mRNA vaccine with a lipid-based nanoparticle as well, while utilizing nucleoside-modified RNA, which encodes the full SARS-CoV-2 spike protein [111].”
MethodMelzi, E., Willis, J. R., Ma, K. M., Lin, Y., Kratochvil, S., Berndsen, Z. T., Landais, E., Kalyuzhniy, O., Nair, U., Warner, J. E., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.003 · Cited by 66
Community Engagement in Vaccination Promotion: Systematic Review and Meta-Analysis
Xie, Y. J., Liao, X., Lin, M., Yang, L., Cheung, K., Zhang, Q., Li, Y., Hao, C., Wang, H., Gao, Y., et al. (2024) · JMIR Public Health and Surveillance · doi:10.2196/49695 · Cited by 68
“A notable illustration is the use of vaccines as a crucial measure to mitigate the COVID-19 pandemic in the past 3 years [3,4].”
BackgroundSritipsukho, P., Khawcharoenporn, T., Siribumrungwong, B., Damronglerd, P., Suwantarat, N., Satdhabudha, A., Chaiyakulsil, C., Sinlapamongkolkul, P., Tangsathapornpong, A., Bunjoungmanee, P., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2037398 · Cited by 71
“The vaccine effectiveness (VE) against wild-type or non-specified strains of SARS-CoV-2 infections were 47–66% for an inactivated viral vaccine [2,3], 62–71% for viral vector vaccines [4–6], and 91–93% for mRNA vaccines [7,8].”
BackgroundWright, B. J., Tideman, S., Diaz, G. A., French, T., Parsons, G., & Robicsek, A. A. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00042-x · Cited by 69
Karunakaran, B., Gupta, R., Patel, P., Salave, S., Sharma, A. K., Desai, D. N., Benival, D. M., & Kommineni, N. (2023) · Vaccines · doi:10.3390/vaccines11030661 · Cited by 70
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
Delivery of mRNA for regulating functions of immune cells
Shi, J. Y., Huang, M., Lu, Z.-D., Du, X., Shen, S., Xu, C., & Wang, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.033 · Cited by 65
Advances and prospects of RNA delivery nanoplatforms for cancer therapy
Attia, M. S., Kijanka, G. S., Nguyen, N., Zhang, J., & An, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.009 · Cited by 66
“This has been seen by investigational vaccines for cancer, as well as influenza, HIV, and Zika viruses, and ultimately, the approved COVID-19 vaccines 29,30 .”
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2022) · Nature Communications · doi:10.1038/s41467-022-28936-y · Cited by 63
Covid-19 vaccines and treatments: we must have raw data, now
Doshi, P., Godlee, F., & Abbasi, K. (2022) · BMJ · doi:10.1136/bmj.o102 · Cited by 63
Durability of immune responses to the BNT162b2 mRNA vaccine
Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 66
Waning of SARS-CoV-2 booster viral-load reduction effectiveness
(2021) · doi:10.1101/2021.12.27.21268424 · Cited by 63
Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 69
Adverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies
Dhamanti, I., Suwantika, A. A., Adlia, A., Yamani, L. N., & Yakub, F. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s400458 · Cited by 62
“29,31–34 Local and systemic adverse events occurred within 7 days of receiving COVID-19 vaccines, with fever, fatigue, and headache being the most common systemic adverse reactions.(35) This finding is consistent with other study that confirmed the incidence rate of frequent adverse effects among healthcare workers wa…”
ResultpH-Dependent Phase Behavior and Stability of Cationic Lipid–mRNA Nanoparticles
Larson, N. R., Hu, G., Wei, Y., Tuesca, A. D., Forrest, M. L., & Middaugh, C. R. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.11.004 · Cited by 62
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors
Waldhorn, I., Holland, R., Goshen‐Lago, T., Shirman, Y., Szwarcwort‐Cohen, M., Benaim, A. R., Shachor‐Meyouhas, Y., Hussein, K., Fahoum, L., Peer, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1072 · Cited by 63
Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
Li, R., Liu, H., Fairley, C. K., Zou, Z., Xie, L., Li, X., Shen, M., Li, Y., & Zhang, L. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.029 · Cited by 60
“In addition, recent serological studies have demonstrated a substantial waning of vaccine-elicited immunity against SARS-CoV-2 infection 6-11 months after administering its second dose ( Chemaitelly et al., 2021 ; Goldberg et al., 2021 ; Thomas et al., 2021 ).”
Poukka, E., Baum, U., Palmu, A. A., Lehtonen, T. O., Salo, H., Nohynek, H., & Leino, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2021.12.032 · Cited by 58
“The effect measure was VE, quantified as 1 minus the hazard ratio adjusted for age, sex, presence of medical conditions predis- *Series that include at least one vaccination with a Covid-19 vaccine other than Comirnaty, Spikevax and Vaxzevria or with a Covid-19 vaccine that was not properly recorded and could thus not…”
InfluentialNew-onset Type 1 Diabetes after COVID-19 mRNA Vaccination
Yano, M., Morioka, T., Natsuki, Y., Sasaki, K., Kakutani, Y., Ochi, A., Yamazaki, Y., Shoji, T., & Emoto, M. (2022) · Internal Medicine · doi:10.2169/internalmedicine.9004-21 · Cited by 59
“Most of the SARS-CoV-2 vaccines administered globally have been messenger ribonucleic acid (mRNA)-1273 (Moderna) and BNT162b2 (PfizerBioNTech), which are mRNA-based vaccines encoding the full-length spike protein of SARS-CoV-2 (1, 3, 4).”
BackgroundNonviral Delivery Systems of mRNA Vaccines for Cancer Gene Therapy
Wang, Y., Zhang, R., Tang, L., & Li, Y. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030512 · Cited by 61
“3%) in preventing the development of COVID-19 [87].”
BackgroundInfluentialMass production system for RNA-loaded lipid nanoparticles using piling up microfluidic devices
Maeki, M., Okada, Y., Uno, S., Sugiura, K., Suzuki, Y., Okuda, K., Sato, Y., Ando, M., Yamazaki, H., Takeuchi, M., et al. (2023) · Applied Materials Today · doi:10.1016/j.apmt.2023.101754 · Cited by 73
Hayawi, K., Shahriar, S., Serhani, M. A., Alashwal, H., & Masud, M. M. (2021) · Vaccines · doi:10.3390/vaccines9111305 · Cited by 62
Thomas, S. J., Perez, J. L., Lockhart, S. P., Hariharan, S., Kitchin, N. R. E., Bailey, R. E., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.046 · Cited by 66
Self-citationSeverity of COVID-19 after Vaccination among Hemodialysis Patients: An Observational Cohort Study
Ashby, D. R., Caplin, B., Corbett, R., Asgari, E., Kumar, N., Sarnowski, A., Hull, R., Makanjuola, D., Cole, N. I., Chen, J., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16621221 · Cited by 59
“Vaccine BNT162b2 46 (53) 79 (42) AZD1222 38 (44) 107 (56) Age, median (IQR) 61 (53–72) 71 (58–79) 63 (52–73) 62 (53–73) Sex Men 622 (59) 58 (67) 117 (62) 797 (60) Ethnicity Asian/other 332 (32) 16 (19) 50 (26) 398 (30) Black 401 (38) 28 (33) 79 (42) 508 (38) White 314 (30) 42 (49) 61 (32) 417 (32) Diabetes 484 (46) 42…”
BackgroundBrasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S. A., Intinis, C. D., Fesi, F., Gizzi, K., Macagno, M., Montone, M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01313-z · Cited by 62
Rappaport, A. R., Hong, S.-J., Scallan, C. D., Gitlin, L., Akoopie, A., Boucher, G. R., Egorova, M., Espinosa, J. A., Fidanza, M., Kachura, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31005-z · Cited by 57
COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
Iacopetta, D., Ceramella, J., Catalano, A. A., Saturnino, C., PELLEGRINO, M. A., Mariconda, A., Longo, P., Sinicropi, M. S., & Aquaro, S. (2022) · Viruses · doi:10.3390/v14030573 · Cited by 65
“Among the numerous variants, the WHO, CDC (USA) and European Centre for Disease Prevention (ECDC) (Europe) highlight some as significant ones and categorize them into two subgroups: variants of concern (VOCs) and variants of interest (VOIs), which are updated when required [51].”
BackgroundInfluentialRole of T cells in severe COVID-19 disease, protection, and long term immunity
Hermens, J. M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01294-9 · Cited by 60
Chillon, T. S., Demircan, K., Heller, R. A., Hirschbil-Bremer, I. M., Diegmann, J., Bachmann, M., Moghaddam, A., & Schomburg, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111714 · Cited by 56
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 64
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Ramu, S. T., Kuruppu, H., Ranasinghe, T., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.621 · Cited by 57
“Although the quantity of neutralizing antibodies that are needed for protection from severe disease or to prevent breakthrough infection is not known, it has been shown that the efficacy of BNT162b2 (Pfizer–BioNTech) vaccine declines with time.(7) Booster doses of BNT162b2 (Pfizer–BioNTech) vaccine resulted in a 11.”
BackgroundOmicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 56
Recent advances in zwitterionic nanoscale drug delivery systems to overcome biological barriers
Ouyang, X., Liu, Y., Zheng, K., Pang, Z., & Peng, S. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100883 · Cited by 66
“Indeed, pairing mRNA with nDDS such as LPNs could overcome the biological barriers and enhance bioavailability in targeted cells, not unlike the anti-COVID-19 vaccine [ 140 ,141 ].”
BackgroundThe Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
Machado, B. A. S., Hodel, K. V. S., Fonseca, L. M. D. S., Mascarenhas, L. A. B., Andrade, L. P. C. D. S., Rocha, V. P. C., Soares, M. B. P., Berglund, P., Duthie, M. S., Reed, S. G., et al. (2021) · Vaccines · doi:10.3390/vaccines9111345 · Cited by 60
COVID-19 Infection in Children: Diagnosis and Management
Zhu, F. H., & Ang, J. Y. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00779-0 · Cited by 58
Moscardino, U. M. M., Musso, P., Inguglia, C., Ceccon, C., Miconi, D., & Rousseau, C. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.018 · Cited by 59
“Introduction substantially [3,4], many people are still reluctant or reject”
Pitzalis, M., Idda, M. L., Lodde, V., Loizedda, A., Lobina, M., Żołędziewska, M., Virdis, F., Delogu, G., Pirinu, F., Marini, M. G., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.781843 · Cited by 52
“The mRNA vaccines BNT162b2 (Pfizer-BioNTech) and mRNA1273 (Moderna) directed against the spike glycoprotein of SARSCoV-2 have proven to be safe and especially effective in protecting against infection and severe forms of COVID-19 (7, 8).”
BackgroundSpinelli, M. A., Peluso, M. J., Lynch, K. L., Yun, C., Glidden, D. V., Henrich, T. J., Deeks, S. G., & Gandhi, M. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1009 · Cited by 51
Lozano‐Rodríguez, R., Valentín‐Quiroga, J., Ortiz, J. A., Martín‐Quirós, A., Pascual‐Iglesias, A., Terrón‐Arcos, V., Montalbán-Hernández, K. M., Casalvilla‐Dueñas, J. C., Bergón-Gutiérrez, M., Alcamí, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110235 · Cited by 54
“…a switch to an anti-RBD neutralizing phenotype (Sokal et al., 2021), it is tempting to speculate that long-term protection already documented for the BNT162b2 vaccine (Thomas et al., 2021) is warranted, based at least in part on the restimulation of these cells during a SARS-CoV-2 reinfection.”
Haşlak, F., Gunalp, A., Çebi, M. N., Yıldız, M., Adroviç, A., Şahin, S., Barut, K., & Kasapçopur, Ö. (2022) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14279 · Cited by 54
Grasselli, G., Zanella, A., Carlesso, E., Florio, G., Canakoglu, A., Bellani, G., Bottino, N., Cabrini, L., Castelli, G. P., Catena, E., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.38871 · Cited by 55
Bellavite, P., Ferraresi, A., & Isidoro, C. (2023) · Biomedicines · doi:10.3390/biomedicines11020451 · Cited by 54
PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
Suah, J. L., Tok, P. S. K., Ong, S. M., Husin, M., Tng, B. H., Sivasampu, S., Thevananthan, T., Appannan, M. R., Zin, F. M., Zin, S. M., et al. (2021) · Vaccines · doi:10.3390/vaccines9121381 · Cited by 53
“3% through six months of follow-up [10].”
Cao, L., Lou, J., Chan, S. Y., Zheng, H., Liu, C., Zhao, S., Li, Q., Mok, C. K. P., Chan, R. W. Y., Chong, M. K. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01877-1 · Cited by 49
“3) 32 [3] BNT162b2 mRNA 92 (88, 94) 38 [4] BNT162b2 mRNA 90 (85, 94) 43 [5] BNT162b2 mRNA 86 (81, 90) 44 [6] AZD1222 Viral vector 81 (72, 87) 38 [7] AZD1222 Viral vector 74.”
Brook, B., Duval, V., Barman, S., Speciner, L., Sweitzer, C., Khanmohammed, A., Menon, M., Foster, K., Ghosh, P., Abedi, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adm8451 · Cited by 52
Bakkers, M. J. G., Ritschel, T., Tiemessen, M. M., Dijkman, J., Zuffianò, A. A., Yu, X., van Overveld, D., Le, L., Voorzaat, R., van Haaren, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50659-5 · Cited by 55
Aliakbarinodehi, N., Niederkofler, S., Emilsson, G., Parkkila, P., Olsén, E., Jing, Y., Sjöberg, M., Agnarsson, B., Lindfors, L., & Höök, F. (2024) · ACS Nano · doi:10.1021/acsnano.4c04519 · Cited by 53
Bigay, J., Grand, R. L., Martinon, F., & Maisonnasse, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932408 · Cited by 57
“Another global concern is the emergence and spread of variants and the cross-protection conferred by the anti-SARSCoV-2 vaccines, which target the initial/prototypic “Wuhan strain” (Hacisuleyman et al., 2021; Naaber et al., 2021; Ricke, 2021; Thomas et al., 2021; Covid World Vaccination Tracker, 2022).”
BackgroundHuman type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Sokal, A., Bastard, P., Chappert, P., Spaeth, G. B., Fourati, S., Vandenberghe, A., Lagouge-Roussey, P., Meyts, I., Gervais, A., Bouvier‐Alias, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220258 · Cited by 50
Farhani, I., Yamchi, A., Madanchi, H., Khazaei, V., Behrouzikhah, M., Abbasi, H., Salehi, M., Moradi, N., & Sanami, S. (2023) · Current Computer - Aided Drug Design · doi:10.2174/1573409919666230612125440 · Cited by 58
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies
Chen, Z., Hu, Y., & Mei, H. (2023) · Advanced Science · doi:10.1002/advs.202303215 · Cited by 52
New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review
Wu, H. H. L., Kalra, P. A., & Chinnadurai, R. (2021) · Vaccines · doi:10.3390/vaccines9111252 · Cited by 49
COVID-19 Vaccines and Autoimmune Hematologic Disorders
Mingot‐Castellano, M. E., Butta, N. V., Canaro, M., Solano, M. D. C. G. D. C., Sánchez‐González, B., Jiménez‐Bárcenas, R., Pascual, C., Caballero‐Navarro, G., Ureña, L. E., González‐López, T. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10060961 · Cited by 49
“Although thrombocytopenia secondary to COVID-19 vaccination had not been reported as a frequent AE in the clinical trials that led to the approval of vaccines [12,39], soon afterwards, regular updates of databases highlighted occasional secondary thrombocytopenia appearance in previously healthy recipients when vaccin…”
BackgroundValanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 49
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 53
Huang, J., Xia, L., Lin, J., Liu, B., Zhao, Y., Xin, C., Ai, X., Cao, W., Zhang, X., Tian, L., et al. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s347729 · Cited by 64
Desmecht, S., Tashkeev, A., Moussaoui, M. E., Maréchal, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863554 · Cited by 52
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.